Pathogenic mutations in BRCA1 and BRCA2 genes are thus predictive biomarkers for PARPi sensitivity in breast, ovarian, pancreatic, and prostate cancers, and are approved as companion test for PARPi indications [3]. This evidence concerns the gene BRCA1 and prostate carcinoma.